Insiders have done their cost/benefit analysis and have

New Post Public Reply Private Reply Replies (1) Message Board
buccaneer1961 shreya #65

Insiders have done their cost/benefit analysis and have been purchasing shares very actively over the past few months. Buying by insiders should never be taken lightly as they are normally privileged to more information than the public and are usually bound by 6-month lock-up periods and other SEC selling rules . Therefore, the fact that insiders are buying into the trend only adds more clout to my current and future bullish sentiment opinion. The recent insider buying details along with share and market value totals are detailed below.

Date

Name

Shares

Value

12/18/2012

Gregory L. Weaver MBA, CPA Chief Financial Officer & Senior Vice President

8,636

23,921

12/10/2012

Max E. Link, PhD Director

14,000

106,400

12/7/2012

Michael H. Tardugno President & Chief Executive Officer

17,271

47,840

12/5/2012

Alberto R. Martínez, MD Director

34,583

112,394

11/15/2012

Robert W. Hooper Director

11,600

60,320

10/15/2012

Alberto R. Martínez, MD Director

2,500

5,900

10/15/2012

Alberto R. Martínez, MD Director

34,542

95,681

9/20/2012

Max E. Link, PhD Director

18,735

79,061

9/20/2012

Max E. Link, PhD Director

34,542

95,681

9/20/2012

Max E. Link, PhD Director

17,083

55,519

9/20/2012

Max E. Link, PhD Director

35,000

95,200

9/14/2012

Michael H. Tardugno President & Chief Executive Officer

1,900

9,576

9/14/2012

Michael H. Tardugno President & Chief Executive Officer

3,100

15,593

9/14/2012

Jeffrey Wayne Church, CPA

2,000

9,860

9/10/2012

Robert W. Hooper Director

3,491

17,280

9/10/2012

Robert W. Hooper Director

1,549

7,698

9/10/2012

Robert W. Hooper Director

3,800

18,848

9/10/2012

Robert W. Hooper Director

100

494

9/10/2012

Robert W. Hooper Director

1,060

5,215

8/29/2012

Robert W. Hooper Director

2,500

11,625

Totals:

247,992

$ 874,106.00

Pfizer ( PFE ) is early in the stages of creating a similar drug and as rumors suggest, is eying Celsion as a prospect for a partnership and eventually a future acquisition. A joint venture was actually signed with Pfizer on February 2012, so an indication of interest and relationships has been established. I know the first thought that comes to mind is possible share devaluation due to competition with Pfizer, an industry behemoth. This is a rational economic consideration, but within the short-term scope of bullish sentiment considered here, I doubt any significant competition will come from Pfizer as they are in the early stages and Celsion's Phase III results are just around the corner. Therefore, it may be better for Pfizer to partner with Celsion and 'piggyback' off their approval and eventually acquire the firm before their valuations increase. With that said, a partnership with or an acquisition by Pfizer would most likely occur after Phase III results come through and success is realized. Both a merger and acquisition would be bullish for CLSN, at least over the short run.

Market Sentiment - Open Interest on Options and Technical Indicators

Fundamental factors are great for defining the underlying strength or weakness of a company and the directional bias of a trend, but when it comes to entry and exit timing everything takes the back seat to technical analysis and sentiment indicators. Recently, CLSN options became available and a great tool for gauging the aggregate attitude of market participants is the change in open interest and volume figures of call and put options on the underlying stock. Since the scope of my analysis is over the short to intermediate-term, I focus on the January 19th and February 16th 2013 option expirations. As a quick refresher, options are contracts attached with the right but not the obligation to buy or sell 100 shares of the underlying stock at the issued strike price. For example, taking a long call position on CLSN with a strike price of 9 and expiration of January 19th 2013 (American Options), has the right but not the obligation to call 100 shares of the underlying stock away from the option writer (short party to the transaction) at the strike price any time before expiration. If expiration occurs and the underlying stock is below the call option strike price, then the option will expire worthless and the purchaser will be out the premium amount paid. The inverse is true for taking long positions in put options - the purchaser of these options pays a premium that allows them the right but not the obligation to "put" 100 shares of the underlying stock back to the writer of the option at the strike price any time before expiration. If the value is below the strike price before expiration, then the put option is in the money and the long party makes a gross profit.

As depicted below, both the January and February option contracts have volume and open interest. On the left hand side, Open interest corresponds to the call options at a given strike price. On the right side of the grid, open interest corresponds to put option contracts. After taking the net amount of open call and open put option interest at every strike price level and within each expiration month, you can see that the net amount increases from 9,854 to 16,871. This means that not only are there 9,854 open January call option contracts for every one put option contract, but the trend continues and increases into the February expiration - an increase of about 71%. This indicates that there are progressively more call option contracts being executed than put options, a bullish sign even if options are being used to hedge positions. Another interesting observation is the open interest of February calls at a $10 strike price; the amount of contracts is substantially higher than any other strike price level. This indicates the demand for contracts at this level and is actually the better bet for going long a call on CLSN.

Taking a long position in January 2013 calls would be too risky as this is the very month that the Phase III results are released and the risk of options expiring worthless due to regulatory delays is much greater than the reward in my opinion. Even though the premiums will be higher for February call options, it's worth the extra month to allow the market time to adjust and recalibrate to the results and any other developments. Furthermore, a $10 strike price is more optimal than say a $9 strike price as the further out of the money will offset a higher premium paid for a later expiration month. Since the Phase III results are truly a make it or break it situation, soaring above $10 dollars by February is not out of the question.

JAN 19 '13

CALLS

PUTS

Open Interest

Volume

Strike Price

Volume

Open Interest

Net Open

1,113.00

67.00

5.50

21.00

1,269.00

(156.00)

2,338.00

100.00

6.00

96.00

1,745.00

593.00

5,332.00

20.00

7.00

15.00

462.00

4,870.00

1,523.00

57.00

8.00

15.00

381.00

1,142.00

1,115.00

92.00

9.00

3.00

85.00

1,030.00

2,544.00

90.00

10.00

-

467.00

2,077.00

308.00

16.00

11.00

-

10.00

298.00

9,854.00

FEB 16 '13

CALLS

PUTS

Open Interest

Volume

Strike Price

Volume

Open Interest

Net Open

184.00

-

5.50

-

181.00

3.00

888.00

63.00

6.00

225.00

2,527.00

(1,639.00)

4,436.00

-

7.00

16.00

800.00

3,636.00

3,314.00

637.00

8.00

5.00

1,896.00

1,418.00

1,015.00

167.00

9.00

-

55.00

960.00

11,402.00

186.00

10.00

58.00

232.00

11,170.00

1,333.00

83.00

11.00

10.00

10.00

1,323.00

16,871.00

*Independent research tools available at http://www.etrade.com (account required to generate data a/o 12/25/12)

The candlestick chart below helps to zoom in on the real-time market action and paints a picture of the psychological and economic forces at play. The sideways action that we are currently experiencing as portrayed in the daily chart below is due to the uncertainty and temporary equilibrium that buyers and sellers are in. Market participants have been waiting for the Phase III results that are due in January and much of the positioning ahead of this announcement has been entered into by long and short traders. Visually, this indifference ahead of Phase III results can be seen on the upper right hand "triangle" pattern. As the resistance and support levels of the triangle converge, the last two candlesticks to develop are what technical analyst refers to as Spinning Tops. The short length of these candles indicates and the open and close of that day was very close together - in other words, low volatility. Times of contracting price usually happen during low volume periods, as can be seen on the lower bar chart. Low volume reflects the market's steady-state as most news, up to now, has been ascertained and participants are waiting for results.

Prior to the lower volatility and indifference, the stock price had a dip, which I'm confident, was and still is a great buying or dollar cost averaging opportunity. From a technical analysis point of view, this dip was revealed many days before by a pattern on the chart known as technical divergence. Mapping the line connecting the tops of the volume candles from late November to Mid-December with the line directly above connecting the lows of the candlesticks reveals that volume began to decrease as price made higher highs - This simply means that price was losing momentum as buyers cashed out their positions. I'm confident the catalyst for this dip was is the anticipated increase in capital gains taxes, a component of the looming fiscal cliff set to take effect on the first of January. Long parties are up quite a bit and many desired to cash in on these profits at a lower tax rate.

(click to enlarge)

Some considerations

Negative EPS and the large amount of short positions on CLSN have been the focus of motivated bears and many unsure bulls. Negative EPS on a medical company relying on Research & Development outflows to secure patents and pass regulatory hurdles is common; even more so with a company such as CLSN that has dipped much less into dilutive capital raising methods, with the exception of minimal equity financing initiatives.

With regards to the high amount of short positions on CLSN , I'm confident this will work in the bulls' favor after Phase III results are made public. Shorts are already experiencing drastic draw-downs as CLSN posts a YTD return of over 300%. Therefore, if investors are assumed to be rational then the majority of these short positions has corresponding stop-losses above their short entry price.These are called "covers" once executed and are effectively buy transactions. Once CLSN breaks out and above the tight range it's currently in and more confidence and directional bias enters the market, the short position stop-losses will be executed and only add bullish fuel to CLSN.

Business relationship disclosure : CenturyFX Group is a team of market analysts. This article was co-written by Armando Izaguirre & Michael Gentilella, managing partners at CenturyFX. We did not receive compensation for this article (other than from Seeking Alpha), and we have no business relationship with any company whose stock is mentioned in this article.

Imunon, Inc. (IMNN) Stock Research Links

IMNN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Graphic Packaging's Q3 2026 Results: Mixed Signals

Updated Category News Views 81

Graphic Packaging's Financial Figures: A Rough Ride Looking at the latest numbers from Graphic Packaging (NYSE: GPK), it's clear that the packaging landscape isn’t all wrapped up in a neat bow. Sure, the top line showed a slight uptick year-on-year with net sales nudging up $2 million to $2,192 million. Volumes were up too—by 1%—but that’s barely a blip when you...

Continue Reading
AMETEK Surpasses Q3 2026 Expectations, Raises Outlook

Updated Category News Views 56

A Banner Quarter for AMETEK Holy smokes, AMETEK has thrown down some numbers for the third quarter of 2026 that would make any seasoned trader sit up and take notice. We’re talking record-breaking across the board: $2.22 billion in sales, marking a whopping 17% increase over last year. Now, that's not just growth—that's rocket fuel. Earnings per share rocketed up with...

Continue Reading
SlidesAI Launches Standalone Platform for Presentations

Updated Category News Views 62

From Add-on to Standalone: SlidesAI's Big Leap You know what they say: time waits for no one, and that seems true in tech too. Those suit-and-tie presentation days? SlidesAI just took a swing at redefining them. Once a trusty sidekick locked into Google Slides, it's now captaining its own ship. Welcome to the SlidesAI standalone presentation platform—where AI meets your...

Continue Reading
Nordic Chips Slash Power Use, Boost Edge AI on Wi-Fi

Updated Category News Views 121

Nordic Semiconductor's Cutting-Edge Leap Let's cut through the noise: Nordic Semiconductor's latest move in the wireless landscape is a big deal, especially if you're the sort counting beans down to the last cent. Their fresh-off-the-press nRF71 Series of Systems-On-Chip (SoCs) pulls off a neat trick: it delivers Wi-Fi, Bluetooth LE, Thread, and edge AI on one chip, and...

Continue Reading
Artprice Bridges Art and AI Across the Hispanic World

Updated Category News Views 11

A Monumental Launch with Deep Roots I've been around long enough to see all sorts of moves in the art world and the tech world. But what Artprice by Artmarket is pulling off here—it’s a doozy. Thierry Ehrmann’s “Diálogo entre un pensador y la IA” just went live in Spanish, and that’s not some paperback thrill ride. We’re talking about an 1,800-page piece of...

Continue Reading
Oracle's $20 Billion Offering: What Investors Need to Know

Updated Category News Views 118

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Continue Reading
Rising Medical Lands Ninth Spot on Inc. 5000

Updated Category News Views 83

Rising Medical's Continued Ascent In a world where the list of high-performing companies is as long as a trader's bad day, Rising Medical Solutions, out of Chicago, has snagged its ninth appearance on the Inc. 5000 list. This isn’t just any roll call; we're talking about a spotlight for America’s fastest-growing private companies—a badge of honor for business...

Continue Reading
Sesame Software's Game-Changer: Smooth CRM Switch

Updated Category News Views 0

Why Leaving Salesforce Isn't as Crazy as It Sounds Stepping away from Salesforce isn't your run-of-the-mill decision for businesses. It’s more like abandoning ship, anticipating lurking dangers: losing cherished data, facing burdensome API restrictions, and fretting over years of trapped history. It’s not as simple as flipping a switch, and that’s what keeps most...

Continue Reading
Envision's Green Ammonia Powers Game-Changing Shipping Milestone

Updated Category News Views 78

Envision's Big Bet on Green Ammonia It's a day to talk about paradigms shifting on the high seas. Envision, a heavy hitter in the green tech arena, just fueled the very first Very Large Ammonia Carrier (VLAC) with their certified green ammonia. Now, that's not just a milestone, it’s like finding a four-leaf clover in the world of maritime decarbonization—a tough nut...

Continue Reading
Exploring Shenzhen's Future Beyond Its Skyline

Updated Category News Views 86

Unveiling the True Spirit of Shenzhen Who's got the guts to look beyond glistening skyscrapers and see what really makes a city tick today? That's what Malcolm Clarke, the maestro behind two Oscar-winning flicks, is doing with his latest documentary, Shenzhen: People Who Build the Future. He's not just swooping in to admire the skyline—he's digging deep, aiming to...

Continue Reading

Top 5 Most Recently Viewed Articles

Applied Optoelectronics Unveils New Employee Equity Grants

Updated Category News Views 206

Applied Optoelectronics Introduces New Equity Grants for Employees In an exciting development, Applied Optoelectronics, Inc. (NASDAQ: AAOI) has announced that its board's Compensation Committee has awarded equity grants to new employees under their inducement plan. This initiative involves granting 11,860 shares of common stock to five new team members, with a specific...

Continue Reading
NextNRG Sees Spectacular Revenue Surge Amid Strategic Growth

Updated Category News Views 252

NextNRG's Impressive October Revenue Growth NextNRG, Inc. (NASDAQ:NXXT), a leader in AI-driven energy innovation, has reported preliminary financial results for October 2025, showcasing significant progress in revenue generation. Highlighting Financial Achievements In October 2025, NextNRG achieved a remarkable revenue of $7.39 million, which marks a staggering 196%...

Continue Reading
Cavallo’s Zach Wetta Optimizes Profit Strategies at Summit

Updated Category News Views 237

Insights from Cavallo's SVP on Profit Enhancements Cavallo, a leader in Order Intelligence, is gearing up to play a vital role at the Community Summit North America, a key event for users of Microsoft business applications. Zach Wetta, the Senior Vice President at Cavallo, will share essential strategies aimed at eradicating profit defects. Transforming Order Management...

Continue Reading
Woodland Family Dental Introduces Comprehensive Website in Spanish

Updated Category News Views 122

Woodland Family Dental Introduces a New Bilingual Website Woodland Family Dental has proudly launched its first official website, marking a significant step forward in enhancing patient experience and accessibility. This new online platform caters particularly to the local community, offering comprehensive dental care information in both English and Spanish. The...

Continue Reading
AMC Stock Faces Challenges Ahead of Earnings Report

Updated Category News Views 101

AMC Stock Struggles Ahead of Key Earnings Report AMC Entertainment Holdings Inc (NASDAQ: AMC) is gearing up for its crucial fourth-quarter earnings announcement. Investors are keen to see how this report will unfold, especially as market analysts predict a loss of 18 cents per share alongside anticipated revenues of $1.30 billion. With such expectations, there is...

Continue Reading